Palliation of Bone Pain in Prostate Cancer Using Chemotherapy and Strontium-89. A Randomized Phase II Study
Strontium-89 is an established alternative for the alleviation of bone pain in prostate cancer. There are few data evaluating the effect on pain of palliative chemotherapy. The aim of this randomized phase II study was to assess and compare the analgesic efficacy of strontium-89 and chemotherapy (FE...
Gespeichert in:
| Veröffentlicht in: | Journal of pain and symptom management 2005-04, Vol.29 (4), p.352-357 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 357 |
|---|---|
| container_issue | 4 |
| container_start_page | 352 |
| container_title | Journal of pain and symptom management |
| container_volume | 29 |
| creator | Nilsson, Sten Strang, Peter Ginman, Claes Zimmermann, Rolf Edgren, Maliha Nordström, Britta Ryberg, Marianne Kälkner, Karl-Mikael Westlin, Jan-Erik |
| description | Strontium-89 is an established alternative for the alleviation of bone pain in prostate cancer. There are few data evaluating the effect on pain of palliative chemotherapy. The aim of this randomized phase II study was to assess and compare the analgesic efficacy of strontium-89 and chemotherapy (FEM
=
5-FU, epirubicin, and mitomycin C) in 35 patients with disseminated, hormone-refractory prostate cancer suffering from persisting bone pain despite analgesic treatment. In order to minimize the risk for imbalances regarding the two patient groups, a double-blind randomization was performed. A significant reduction in pain intensity and pain frequency was registered in both patient groups (P < 0.01 in both groups after 3 weeks). Side effects were generally mild in the strontium-89 group and significantly more severe in the FEM group. The effect of FEM on pain is surprising as chemotherapy has generally only limited effect on tumor growth in bone metastases due to prostate cancer. A possible explanation is that FEM has an inhibitory activity on the inflammatory component of metastases. |
| doi_str_mv | 10.1016/j.jpainsymman.2004.07.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_581055</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0885392405000527</els_id><sourcerecordid>67796518</sourcerecordid><originalsourceid>FETCH-LOGICAL-c494t-5d3dd034c609bf48558ea0f3acf1af370a54b50b4d096e7eec1092066337dcf13</originalsourceid><addsrcrecordid>eNqNkVGL1DAQx4so3t7pV5D4oG-tk03TpI9n0XPhwEW955AmUzd7bVOTVlk_vTm2eD4KgYThNzPh_8uy1xQKCrR6dyyOk3ZjPA2DHostQFmAKADkk2xDpWB5xSl7mm1ASp6zelteZJcxHgGAs4o9zy4ol1wIJjfZ_V73vdOz8yPxHXnvRyT7NJuksw8-znpG0ujRYCB30Y3fSXPAwc8HDHo6ET1a8nUOfpzdMuSyLsg1-ZKKfnC_0ZL9QUcku11iFnt6kT3rdB_x5XpfZXcfP3xrPuW3n292zfVtbsq6nHNumbXASlNB3Xal5Fyiho5p01HdMQGaly2HtrRQVygQDYV6C1XFmLCJYVdZfp4bf-G0tGoKbtDhpLx2ai3dpxcqLilwnvi3Z34K_seCcVaDiwb7Xo_ol6gqIeqUqExgfQZNSiYG7P6OpqAezKij-seMejCjQKhkJvW-Wpcs7YD2sXNVkYA3K6Cj0X0XUuguPnKVkKKmInHNmcMU4U-HQUXjMAmyLqCZlfXuP77zB4LNswE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67796518</pqid></control><display><type>article</type><title>Palliation of Bone Pain in Prostate Cancer Using Chemotherapy and Strontium-89. A Randomized Phase II Study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Nilsson, Sten ; Strang, Peter ; Ginman, Claes ; Zimmermann, Rolf ; Edgren, Maliha ; Nordström, Britta ; Ryberg, Marianne ; Kälkner, Karl-Mikael ; Westlin, Jan-Erik</creator><creatorcontrib>Nilsson, Sten ; Strang, Peter ; Ginman, Claes ; Zimmermann, Rolf ; Edgren, Maliha ; Nordström, Britta ; Ryberg, Marianne ; Kälkner, Karl-Mikael ; Westlin, Jan-Erik</creatorcontrib><description>Strontium-89 is an established alternative for the alleviation of bone pain in prostate cancer. There are few data evaluating the effect on pain of palliative chemotherapy. The aim of this randomized phase II study was to assess and compare the analgesic efficacy of strontium-89 and chemotherapy (FEM
=
5-FU, epirubicin, and mitomycin C) in 35 patients with disseminated, hormone-refractory prostate cancer suffering from persisting bone pain despite analgesic treatment. In order to minimize the risk for imbalances regarding the two patient groups, a double-blind randomization was performed. A significant reduction in pain intensity and pain frequency was registered in both patient groups (P < 0.01 in both groups after 3 weeks). Side effects were generally mild in the strontium-89 group and significantly more severe in the FEM group. The effect of FEM on pain is surprising as chemotherapy has generally only limited effect on tumor growth in bone metastases due to prostate cancer. A possible explanation is that FEM has an inhibitory activity on the inflammatory component of metastases.</description><identifier>ISSN: 0885-3924</identifier><identifier>EISSN: 1873-6513</identifier><identifier>DOI: 10.1016/j.jpainsymman.2004.07.008</identifier><identifier>PMID: 15857738</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Biological and medical sciences ; Bone Neoplasms - complications ; Bone Neoplasms - drug therapy ; Bone Neoplasms - radiotherapy ; Bone Neoplasms - secondary ; chemotherapy ; Double-Blind Method ; Epirubicin - administration & dosage ; Fluorouracil - administration & dosage ; Humans ; inflammation ; Male ; Medical sciences ; Mitomycin - administration & dosage ; Neoplasms ; pain ; Pain - diagnosis ; Pain - etiology ; Pain - prevention & control ; Pain Measurement ; Palliative Care - methods ; Pharmacology. Drug treatments ; prostate ; Prostatic Neoplasms - complications ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - radiotherapy ; Radiopharmaceuticals - therapeutic use ; Severity of Illness Index ; strontium ; Strontium - therapeutic use ; Treatment Outcome</subject><ispartof>Journal of pain and symptom management, 2005-04, Vol.29 (4), p.352-357</ispartof><rights>2005 U.S. Cancer Pain Relief Committee</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c494t-5d3dd034c609bf48558ea0f3acf1af370a54b50b4d096e7eec1092066337dcf13</citedby><cites>FETCH-LOGICAL-c494t-5d3dd034c609bf48558ea0f3acf1af370a54b50b4d096e7eec1092066337dcf13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jpainsymman.2004.07.008$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16787917$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15857738$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:1941483$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Nilsson, Sten</creatorcontrib><creatorcontrib>Strang, Peter</creatorcontrib><creatorcontrib>Ginman, Claes</creatorcontrib><creatorcontrib>Zimmermann, Rolf</creatorcontrib><creatorcontrib>Edgren, Maliha</creatorcontrib><creatorcontrib>Nordström, Britta</creatorcontrib><creatorcontrib>Ryberg, Marianne</creatorcontrib><creatorcontrib>Kälkner, Karl-Mikael</creatorcontrib><creatorcontrib>Westlin, Jan-Erik</creatorcontrib><title>Palliation of Bone Pain in Prostate Cancer Using Chemotherapy and Strontium-89. A Randomized Phase II Study</title><title>Journal of pain and symptom management</title><addtitle>J Pain Symptom Manage</addtitle><description>Strontium-89 is an established alternative for the alleviation of bone pain in prostate cancer. There are few data evaluating the effect on pain of palliative chemotherapy. The aim of this randomized phase II study was to assess and compare the analgesic efficacy of strontium-89 and chemotherapy (FEM
=
5-FU, epirubicin, and mitomycin C) in 35 patients with disseminated, hormone-refractory prostate cancer suffering from persisting bone pain despite analgesic treatment. In order to minimize the risk for imbalances regarding the two patient groups, a double-blind randomization was performed. A significant reduction in pain intensity and pain frequency was registered in both patient groups (P < 0.01 in both groups after 3 weeks). Side effects were generally mild in the strontium-89 group and significantly more severe in the FEM group. The effect of FEM on pain is surprising as chemotherapy has generally only limited effect on tumor growth in bone metastases due to prostate cancer. A possible explanation is that FEM has an inhibitory activity on the inflammatory component of metastases.</description><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Bone Neoplasms - complications</subject><subject>Bone Neoplasms - drug therapy</subject><subject>Bone Neoplasms - radiotherapy</subject><subject>Bone Neoplasms - secondary</subject><subject>chemotherapy</subject><subject>Double-Blind Method</subject><subject>Epirubicin - administration & dosage</subject><subject>Fluorouracil - administration & dosage</subject><subject>Humans</subject><subject>inflammation</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mitomycin - administration & dosage</subject><subject>Neoplasms</subject><subject>pain</subject><subject>Pain - diagnosis</subject><subject>Pain - etiology</subject><subject>Pain - prevention & control</subject><subject>Pain Measurement</subject><subject>Palliative Care - methods</subject><subject>Pharmacology. Drug treatments</subject><subject>prostate</subject><subject>Prostatic Neoplasms - complications</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>Radiopharmaceuticals - therapeutic use</subject><subject>Severity of Illness Index</subject><subject>strontium</subject><subject>Strontium - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0885-3924</issn><issn>1873-6513</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkVGL1DAQx4so3t7pV5D4oG-tk03TpI9n0XPhwEW955AmUzd7bVOTVlk_vTm2eD4KgYThNzPh_8uy1xQKCrR6dyyOk3ZjPA2DHostQFmAKADkk2xDpWB5xSl7mm1ASp6zelteZJcxHgGAs4o9zy4ol1wIJjfZ_V73vdOz8yPxHXnvRyT7NJuksw8-znpG0ujRYCB30Y3fSXPAwc8HDHo6ET1a8nUOfpzdMuSyLsg1-ZKKfnC_0ZL9QUcku11iFnt6kT3rdB_x5XpfZXcfP3xrPuW3n292zfVtbsq6nHNumbXASlNB3Xal5Fyiho5p01HdMQGaly2HtrRQVygQDYV6C1XFmLCJYVdZfp4bf-G0tGoKbtDhpLx2ai3dpxcqLilwnvi3Z34K_seCcVaDiwb7Xo_ol6gqIeqUqExgfQZNSiYG7P6OpqAezKij-seMejCjQKhkJvW-Wpcs7YD2sXNVkYA3K6Cj0X0XUuguPnKVkKKmInHNmcMU4U-HQUXjMAmyLqCZlfXuP77zB4LNswE</recordid><startdate>20050401</startdate><enddate>20050401</enddate><creator>Nilsson, Sten</creator><creator>Strang, Peter</creator><creator>Ginman, Claes</creator><creator>Zimmermann, Rolf</creator><creator>Edgren, Maliha</creator><creator>Nordström, Britta</creator><creator>Ryberg, Marianne</creator><creator>Kälkner, Karl-Mikael</creator><creator>Westlin, Jan-Erik</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>20050401</creationdate><title>Palliation of Bone Pain in Prostate Cancer Using Chemotherapy and Strontium-89. A Randomized Phase II Study</title><author>Nilsson, Sten ; Strang, Peter ; Ginman, Claes ; Zimmermann, Rolf ; Edgren, Maliha ; Nordström, Britta ; Ryberg, Marianne ; Kälkner, Karl-Mikael ; Westlin, Jan-Erik</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c494t-5d3dd034c609bf48558ea0f3acf1af370a54b50b4d096e7eec1092066337dcf13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Bone Neoplasms - complications</topic><topic>Bone Neoplasms - drug therapy</topic><topic>Bone Neoplasms - radiotherapy</topic><topic>Bone Neoplasms - secondary</topic><topic>chemotherapy</topic><topic>Double-Blind Method</topic><topic>Epirubicin - administration & dosage</topic><topic>Fluorouracil - administration & dosage</topic><topic>Humans</topic><topic>inflammation</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mitomycin - administration & dosage</topic><topic>Neoplasms</topic><topic>pain</topic><topic>Pain - diagnosis</topic><topic>Pain - etiology</topic><topic>Pain - prevention & control</topic><topic>Pain Measurement</topic><topic>Palliative Care - methods</topic><topic>Pharmacology. Drug treatments</topic><topic>prostate</topic><topic>Prostatic Neoplasms - complications</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>Radiopharmaceuticals - therapeutic use</topic><topic>Severity of Illness Index</topic><topic>strontium</topic><topic>Strontium - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nilsson, Sten</creatorcontrib><creatorcontrib>Strang, Peter</creatorcontrib><creatorcontrib>Ginman, Claes</creatorcontrib><creatorcontrib>Zimmermann, Rolf</creatorcontrib><creatorcontrib>Edgren, Maliha</creatorcontrib><creatorcontrib>Nordström, Britta</creatorcontrib><creatorcontrib>Ryberg, Marianne</creatorcontrib><creatorcontrib>Kälkner, Karl-Mikael</creatorcontrib><creatorcontrib>Westlin, Jan-Erik</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Journal of pain and symptom management</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nilsson, Sten</au><au>Strang, Peter</au><au>Ginman, Claes</au><au>Zimmermann, Rolf</au><au>Edgren, Maliha</au><au>Nordström, Britta</au><au>Ryberg, Marianne</au><au>Kälkner, Karl-Mikael</au><au>Westlin, Jan-Erik</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Palliation of Bone Pain in Prostate Cancer Using Chemotherapy and Strontium-89. A Randomized Phase II Study</atitle><jtitle>Journal of pain and symptom management</jtitle><addtitle>J Pain Symptom Manage</addtitle><date>2005-04-01</date><risdate>2005</risdate><volume>29</volume><issue>4</issue><spage>352</spage><epage>357</epage><pages>352-357</pages><issn>0885-3924</issn><eissn>1873-6513</eissn><abstract>Strontium-89 is an established alternative for the alleviation of bone pain in prostate cancer. There are few data evaluating the effect on pain of palliative chemotherapy. The aim of this randomized phase II study was to assess and compare the analgesic efficacy of strontium-89 and chemotherapy (FEM
=
5-FU, epirubicin, and mitomycin C) in 35 patients with disseminated, hormone-refractory prostate cancer suffering from persisting bone pain despite analgesic treatment. In order to minimize the risk for imbalances regarding the two patient groups, a double-blind randomization was performed. A significant reduction in pain intensity and pain frequency was registered in both patient groups (P < 0.01 in both groups after 3 weeks). Side effects were generally mild in the strontium-89 group and significantly more severe in the FEM group. The effect of FEM on pain is surprising as chemotherapy has generally only limited effect on tumor growth in bone metastases due to prostate cancer. A possible explanation is that FEM has an inhibitory activity on the inflammatory component of metastases.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>15857738</pmid><doi>10.1016/j.jpainsymman.2004.07.008</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-3924 |
| ispartof | Journal of pain and symptom management, 2005-04, Vol.29 (4), p.352-357 |
| issn | 0885-3924 1873-6513 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_581055 |
| source | MEDLINE; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Biological and medical sciences Bone Neoplasms - complications Bone Neoplasms - drug therapy Bone Neoplasms - radiotherapy Bone Neoplasms - secondary chemotherapy Double-Blind Method Epirubicin - administration & dosage Fluorouracil - administration & dosage Humans inflammation Male Medical sciences Mitomycin - administration & dosage Neoplasms pain Pain - diagnosis Pain - etiology Pain - prevention & control Pain Measurement Palliative Care - methods Pharmacology. Drug treatments prostate Prostatic Neoplasms - complications Prostatic Neoplasms - drug therapy Prostatic Neoplasms - radiotherapy Radiopharmaceuticals - therapeutic use Severity of Illness Index strontium Strontium - therapeutic use Treatment Outcome |
| title | Palliation of Bone Pain in Prostate Cancer Using Chemotherapy and Strontium-89. A Randomized Phase II Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T16%3A18%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Palliation%20of%20Bone%20Pain%20in%20Prostate%20Cancer%20Using%20Chemotherapy%20and%20Strontium-89.%20A%20Randomized%20Phase%20II%20Study&rft.jtitle=Journal%20of%20pain%20and%20symptom%20management&rft.au=Nilsson,%20Sten&rft.date=2005-04-01&rft.volume=29&rft.issue=4&rft.spage=352&rft.epage=357&rft.pages=352-357&rft.issn=0885-3924&rft.eissn=1873-6513&rft_id=info:doi/10.1016/j.jpainsymman.2004.07.008&rft_dat=%3Cproquest_swepu%3E67796518%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67796518&rft_id=info:pmid/15857738&rft_els_id=S0885392405000527&rfr_iscdi=true |